Faculty profile

Bernard Thébaud

Back to faculty

Full ProfessorPediatricsUniversity of Ottawa

Bernard Thébaud

Full Professor

Pediatrics

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
9 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 11 research grants (11 CIHR), most recently in 2025.
Supervised 6 trainees who won CIHR awards, most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Newborn Stem Cells Preterm Birth Regenerative Medicine Lung Mesenchymal Stromal Cells Lung Injury Animal Models

Latest papers

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.
Gene therapy · 2026
Helping Underdeveloped Lungs with Cells (HULC-2): mesenchymal stromal cells in extreme preterm infants at risk of developing bronchopulmonary dysplasia - a study protocol of a phase 2 multicentre double blind randomised controlled trial in Canada.
BMJ open · 2026 · senior author
Efficient and safe lung gene delivery using AAV6.2FF in neonatal pigs demonstrates pediatric translational potential.
Molecular therapy. Advances · 2026

All 15 publications

Latest funding

LabPartners-Nexus: Embedding patient engagement in preclinical research across Canada
CIHR · 2026 · Co-investigator
$401,626
Lung specific AAV gene therapy for inherited disorders of surfactant metabolism
CIHR · 2025 · Nominated PI
$1,071,000
Unveiling the potential of next generation cell therapies: induced pluripotent stem cells derived mesenchymal stromal cells for bronchopulmonary dysplasia
CIHR · 2025 · Supervisor
$140,000

All 30 grants and awards

15 publications.

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Zielinska N, Howard EL, Stevens BAY, Goens MM, Campbell ESB, Hughes ME, Pei Y, Xu L, Achuthan A, Vadivel A, Apostol A, He X, Zheng D, Gordon DB, Srinivas RR, Nielsen AAK, Caswell JL, Arroyo LG, Yuen DA, Thebaud B, Wootton SK

Gene therapy2026

DOI: 10.1038/s41434-026-00629-x PMID: 42380600

Helping Underdeveloped Lungs with Cells (HULC-2): mesenchymal stromal cells in extreme preterm infants at risk of developing bronchopulmonary dysplasia - a study protocol of a phase 2 multicentre double blind randomised controlled trial in Canada.

Renesme L, Ferretti E, Horth C, Grimwood R, Da Sylva L, Olson V, Cyr-Depauw C, Freund D, Rüdiger M, Möbius MA, Hodgins S, Khan S, Courtman D, Fergusson DA, Thebaud B

BMJ open2026Senior author

DOI: 10.1136/bmjopen-2025-112385 PMID: 42409407

Efficient and safe lung gene delivery using AAV6.2FF in neonatal pigs demonstrates pediatric translational potential.

Zielinska N, Howard EL, Yang C, Stevens BAY, Goens MM, Pei Y, Thompson B, Caswell JL, Thebaud B, Wey D, Valverde A, Arroyo LG, Wootton SK

Molecular therapy. Advances2026

DOI: 10.1016/j.omta.2026.201739 PMID: 42232221

A preclinical systematic review and meta-analysis assessing the effect of biological sex in lipopolysaccharide-induced acute lung injury.

Kuhar E, Chander N, Stewart DJ, Jahandideh F, Zhang H, Kristof AS, Bastarache JA, Schmidt EP, Taljaard M, Thebaud B, Engelberts D, Fergusson DA, Lalu MM

American journal of physiology. Lung cellular and molecular physiology2024

DOI: 10.1152/ajplung.00336.2023 PMID: 38349120

Analysis of the impact of pluronic acid on the thermal stability and infectivity of AAV6.2FF.

Thomas SP, Spinelli MM, Rghei AD, Lopes JA, Zielinska N, McLeod BM, Pei Y, Zhang W, Thebaud B, Karimi K, Wootton SK

BMC biotechnology2024

DOI: 10.1186/s12896-024-00853-6 PMID: 38664752

Effects of prophylactic hydrocortisone in a tertiary Canadian NICU.

de Souza M, Melika R, Thebaud B, Barrowman NJ, Tsampalieros A, Lemyre B

Archives of disease in childhood. Fetal and neonatal edition2024

DOI: 10.1136/archdischild-2023-325913 PMID: 37827815

A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency.

Thomas SP, Domm JM, van Vloten JP, Xu L, Vadivel A, Yates JGE, Pei Y, Ingrao J, van Lieshout LP, Jackson SR, Minott JA, Achuthan A, Mehrani Y, McAusland TM, Zhang W, Karimi K, Vaughan AE, de Jong J, Kang MH, Thebaud B, Wootton SK

Molecular therapy : the journal of the American Society of Gene Therapy2023

DOI: 10.1016/j.ymthe.2023.10.002 PMID: 37805711

Advances in neonatal cell therapies: Proceedings of the First Neonatal Cell Therapies Symposium (2022).

Malhotra A, Thebaud B, Paton MCB, Fleiss B, Papagianis P, Baker E, Bennet L, Yawno T, Elwood N, Campbell B, Chand K, Zhou L, Penny T, Nguyen T, Pepe S, Gunn AJ, McDonald CA

Pediatric research2023

DOI: 10.1038/s41390-023-02707-x PMID: 37380752

Landscape analysis for a neonatal disease progression model of bronchopulmonary dysplasia: Leveraging clinical trial experience and real-world data.

Barrett JS, Cala Pane M, Knab T, Roddy W, Beusmans J, Jordie E, Singh K, Davis JM, Romero K, Padula M, Thebaud B, Turner M

Frontiers in pharmacology2022

DOI: 10.3389/fphar.2022.988974 PMID: 36313352

Establishment of a consensus definition for mesenchymal stromal cells (MSC) and reporting guidelines for clinical trials of MSC therapy: a modified Delphi study protocol.

Renesme L, Cobey KD, Le M, Lalu MM, Thebaud B

BMJ open2021Senior author

DOI: 10.1136/bmjopen-2021-054740 PMID: 34620674

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Bernard Thébaud

Research

Latest papers

Latest funding

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Helping Underdeveloped Lungs with Cells (HULC-2): mesenchymal stromal cells in extreme preterm infants at risk of developing bronchopulmonary dysplasia - a study protocol of a phase 2 multicentre double blind randomised controlled trial in Canada.

Efficient and safe lung gene delivery using AAV6.2FF in neonatal pigs demonstrates pediatric translational potential.

A preclinical systematic review and meta-analysis assessing the effect of biological sex in lipopolysaccharide-induced acute lung injury.

Analysis of the impact of pluronic acid on the thermal stability and infectivity of AAV6.2FF.

Effects of prophylactic hydrocortisone in a tertiary Canadian NICU.

A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency.

Advances in neonatal cell therapies: Proceedings of the First Neonatal Cell Therapies Symposium (2022).

Landscape analysis for a neonatal disease progression model of bronchopulmonary dysplasia: Leveraging clinical trial experience and real-world data.

Establishment of a consensus definition for mesenchymal stromal cells (MSC) and reporting guidelines for clinical trials of MSC therapy: a modified Delphi study protocol.

LabPartners-Nexus: Embedding patient engagement in preclinical research across Canada

Lung specific AAV gene therapy for inherited disorders of surfactant metabolism

Unveiling the potential of next generation cell therapies: induced pluripotent stem cells derived mesenchymal stromal cells for bronchopulmonary dysplasia

Extracellular vesicles: new biomarkers and therapeutic potential for neonatal lung injury

LabPartners-Nexus: Embedding patient engagement in preclinical research across Canada's Strategy for Patient-Oriented Research (SPOR) Support units.

Therapeutic potential of stem cells in lung injury

Novel gene therapy platform for monogenetic lung diseases

Helping Underdeveloped Lungs with Cells (HULC-2) - A Randomized Controlled Trial to test the efficacy of umbilical cord-derived mesenchymal stromal cells (UC-MSC) in reducing respiratory morbidity in preterm infants at risk of bronchopulmonary dysplasia (BPD)

Canada Research Chair - Tier 1

Helping Underdeveloped Lungs with Cells (HULC-2) - A Randomized Controlled Trial to test the efficacy of umbilical cord-derived mesenchymal stromal cells (UC-MSC) in reducing respiratory morbidity in preterm infants at risk of bronchopulmonary dysplasia (BPD)

Frequent collaborators

Wei Zhang

Haibo Zhang

Fabio Rossi

David Courtman

Ryan McGinn

Brigitte Lemyre

Judy Illes

Emanuela Ferretti

Dawn Stacey

Alison Fox-Robichaud

Monica Taljaard

Lauralyn McIntyre

Mingyao Liu